Abstract
COVID-19 convalescent plasma (CCP) is widely used as a treatment. While safety data are enough, high-level evidences of efficacy are still missing. We summarize here the results from randomized controlled trials (RCT) published to date and analyze their flaws and biases. We then provide suggestions for next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.
Keywords: COVID19; Convalescent plasma; Randomized clinical trial.
All Keywords
【저자키워드】 convalescent plasma, randomized clinical trial, COVID19, 【초록키워드】 COVID-19, Randomized controlled trial, Treatment, convalescent plasma, randomized clinical trial, Efficacy, clinical trial, Randomized controlled trials, RCT, therapeutic, outcome measures, RCTs, Evidence, dose, CCP, therapeutic dose, control arm, disease stage, biases, while, specification, 【제목키워드】 Efficacy, Trial,
【저자키워드】 convalescent plasma, randomized clinical trial, COVID19, 【초록키워드】 COVID-19, Randomized controlled trial, Treatment, convalescent plasma, randomized clinical trial, Efficacy, clinical trial, Randomized controlled trials, RCT, therapeutic, outcome measures, RCTs, Evidence, dose, CCP, therapeutic dose, control arm, disease stage, biases, while, specification, 【제목키워드】 Efficacy, Trial,
{{{ 추상적인 }}}
COVID-19 회복기 혈장(CCP)은 치료제로 널리 사용됩니다. 안전성 데이터는 충분하지만 효능에 대한 높은 수준의 증거는 여전히 부족합니다. 지금까지 발표된 무작위 대조 시험(RCT)의 결과를 요약하고 결함과 편향을 분석합니다. 그런 다음 CCP의 사양, 치료 용량, 시기, 대조군, 질병 단계 및 결과 측정에 대해 논의하는 다음 CCP RCT에 대한 제안을 제공합니다.
{{ 키워드: }} 코로나19; 회복기 혈장; 무작위 임상 시험.